The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUniphar Regulatory News (UPR)

Share Price Information for Uniphar (UPR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 223.00
Bid: 220.00
Ask: 226.00
Change: 0.00 (0.00%)
Spread: 6.00 (2.727%)
Open: 223.00
High: 223.00
Low: 223.00
Prev. Close: 223.00
UPR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

11 May 2023 07:00

RNS Number : 0016Z
Uniphar PLC
11 May 2023
 

 

 

AGM Statement

 

 

Dublin, London | 11 May 2023

 

 

Uniphar plc (the "Group" or "Uniphar") is holding its AGM today at 11am BST at the office of William Fry, LLP, 6th Floor, 2 Grand Canal Square, Dublin 2, D02 A342, Ireland.

 

At the AGM, Maurice Pratt, Chairman of Uniphar, will make the following statement:

 

"I am pleased to say that 2022 was another successful year for Uniphar, with further progress made towards our financial and strategic objectives. The Group delivered a strong financial performance, in line with the Board's expectations. Building on our robust performance in the previous year, the Group delivered 5.7% organic gross profit growth, with organic growth across all divisions and an outperformance in our Supply Chain & Retail division. EBITDA increased to €98m reflecting reported growth of 13.4% and the Group ended the year with strong liquidity and modest leverage of 1.0x, underpinning the Group's disciplined approach to capital allocation and cash conversion.

 

During the year, we continued to make significant strategic progress across each division and enhanced our platforms through both organic investment and M&A that will ensure continued, resilient growth through 2023 and beyond:

 

§ In Product Access, the acquisitions of BModesto Group and Orspec Pharma provide significant capability across continental Europe and the Asia Pacific region. These assets, which we will continue to invest in, add significant scale and reach to our global Product Access platform.

 

§ In Commercial & Clinical, Boston headquartered Inspired Health broadens our service offering through high value market research consultancy services. We also progressed our European commercialisation platform through an organic investment in a highly skilled pan-European Medical Affairs team.

 

§ In Supply Chain & Retail, the acquisition of McCauley Pharmacy Group, who are the Irish market leaders in health, wellbeing and beauty products, adds significant capability to our higher margin retail offering. We also announced a multi-year investment in a new distribution facility which will future-proof our Supply Chain & Retail business and support future growth across the wider Group.

 

Uniphar has traded in line with the Board's expectations in the first four months of 2023 and remains well positioned to deliver organic gross profit growth across all divisions and to deliver on expectations for the full year.

 

Sustainability continues to form a key part of Uniphar's culture and business practices. Initiatives such as our hugely successful Unity for Hope charity event, and the launch of our two Employee Resource Groups - the Rainbow Alliance and the Women's Alliance demonstrate our commitment to creating a sustainable workplace. Our teams also made progress under our Environmental pillar, improving our carbon footprint initiatives and focusing on ways to further decarbonise our business. We completed our first Scope 3 assessment, highlighting the opportunity for a collaborative approach with our suppliers to reduce our collective impact on the environment. Finally, our commitment to maintaining the highest standards of corporate governance across the Group continued in 2022, where the Board adopted the UK Corporate Governance Code, achieving another important milestone on our journey as a publicly quoted company.

 

The continued success of the business in 2022 could not have been delivered without the commitment, ingenuity and "can-do" spirit of our Uniphar colleagues worldwide, who continued to deliver for our customers, the pharmacies, hospitals, manufacturers and patients we serve throughout 2022, while navigating the various challenges presented during the period, including unprecedented global cost inflation and supply chain disruption.

 

I would like to thank all of our Uniphar colleagues, management and my fellow Directors for the huge effort they have put in over the past 12 months, and for their continued dedication and commitment. Finally, I would like to thank our shareholders, executive team and all our teams worldwide for their loyalty, hard work and dedication during 2022."

 

--- ENDS ---

 

 

 

For further details contact:

 

Uniphar Group

 

Tel: +353 (0) 1 428 7777

Allan Smylie, Head of Strategy and IR

Davy (Joint Corporate Broker, Nominated Advisor and

Euronext Growth Listing Sponsor)

 

Tel: +353 (0) 1 679 6363

Daragh O'Reilly

Niall Gilchrist

Ivan Murphy

RBC Capital Markets (Joint Corporate Broker)

 

Tel: +44 (0) 20 7653 4000

Jonathan Hardy

Jamil Miah

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

 

Tel: +44 (0) 20 7710 7600

Matt Blawat

Ben Maddison

Francis North

Q4 PR

 

Tel: +353 (0) 1 475 1444

Iarla Mongey, Public Relations Advisor to Uniphar Group

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMFLFSEEAIILIV
Date   Source Headline
26th Apr 20241:48 pmRNSHolding(s) in Company
15th Apr 20249:00 amRNSDirector/PDMR Shareholding
5th Apr 20247:00 amRNSNotice of AGM & Annual Report
27th Feb 20247:00 amRNS2023 Preliminary Results
6th Feb 202410:30 amRNSHolding(s) in Company
30th Jan 20247:00 amRNSDirectorate Change
30th Jan 20247:00 amRNSFull Year Trading Update and Notice of Results
17th Jan 20247:00 amRNSDirectorate Change
24th Nov 202311:20 amRNSHolding(s) in Company
9th Oct 202311:00 amRNSDirector/PDMR Shareholding
6th Oct 20237:00 amRNSDirector/PDMR Shareholding
4th Oct 20237:00 amRNSDirector/PDMR Shareholding
21st Sep 20233:33 pmRNSHolding(s) in Company
19th Sep 20239:29 amRNSHolding(s) in Company
14th Sep 20233:00 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNS2023 Interim Results
4th Sep 20237:00 amRNSHolding(s) in Company
1st Aug 20232:45 pmRNSHolding(s) in Company
26th Jul 20237:00 amRNSHalf Year Trading Update and Notice of Results
14th Jun 20235:00 pmRNSHolding(s) in Company
11th May 20233:32 pmRNSAGM Results
11th May 20237:00 amRNSAGM Statement
3rd May 20237:00 amRNSHolding(s) in Company
6th Apr 20237:00 amRNSNotice of AGM & Annual Report & Dividend Update
3rd Mar 20237:00 amRNSExecutive Restricted Share Plan Dealings
1st Mar 20233:00 pmRNSDirector/PDMR Shareholding
28th Feb 20237:00 amRNS2022 Preliminary Results
3rd Feb 20237:00 amRNSHolding(s) in Company
2nd Feb 20237:00 amRNSCompletion of McCauley Acquisition
31st Jan 20237:00 amRNSFull Year Trading Update and Notice of Results
25th Jan 20237:00 amRNSHolding(s) in Company
16th Dec 20227:00 amRNSNavi acquisition not cleared by CCPC
8th Dec 20224:06 pmRNSHolding(s) in Company
2nd Dec 20227:00 amRNSNew Share Option Plan
21st Nov 20227:00 amRNSAcquisition of BModesto Group
4th Oct 20227:00 amRNSAcquisition of healthcare agency Inspired Health
19th Sep 20227:00 amRNSAcquisition of McCauley Pharmacy Group
14th Sep 20229:08 amRNSDirector/PDMR Shareholding
30th Aug 20227:00 amRNS2022 Interim Results
26th Jul 20227:00 amRNSHalf Year Trading Update and Notice of Results
11th May 20224:16 pmRNSResult of AGM
11th May 20227:00 amRNSAGM Statement
7th Apr 20227:00 amRNSNotice of AGM & Annual Report
3rd Mar 20227:31 amRNSDirector/PDMR Shareholding
3rd Mar 20227:29 amRNSExecutive Restricted Share Plan Dealings
1st Mar 20227:00 amRNS2021 Preliminary Results
21st Feb 20228:00 amRNSHolding(s) in Company
26th Jan 20227:00 amRNSFull Year Trading Update & Notice of Results
23rd Dec 20217:00 amRNSAcquisitions of E4H, Devonshire and Navi Group
17th Dec 20217:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.